Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
13 Cards in this Set
- Front
- Back
|
Amplification of ____ bypasses therapeutic effect of ______
|
MET
Erlotinib/Tarceva (EGFR inhibitor) |
|
|
PLX4032/Vemurafenib side effects
|
low-grade squamous cell carcinoma
|
|
|
COT
|
activates MEK (& ERK)
|
|
|
use combination of ____ & ____ inhibitors in melanoma???
|
BRaf
MEK |
|
|
Gleevec binds to
|
inactive form of Bcr-Abl
|
|
|
more than 50 point mutations
|
can cause gleevec resistance
|
|
|
Dasatinib
|
second generation bcr-abl inhibitor
|
|
|
Use gleevec
|
in combination with other bcr-abl inhibitors (dasatinib) and downstream abl target inhibitors
|
|
|
STAR
|
Study of Tamoxifen and Raloxifene
showed Raloxifene less side effects (uterine cancer) less potent only 78% as effective as tamoxifen at preventing invasive breast cancer |
|
|
flavopiridol
|
broad spectrum CDK inhibitor
ATP competitive inhibitor not very good in phase II clinical trials - ok for leukemia |
|
|
Gemcitabine
|
ns analogue (anti-metabolite)
initially effective in pancreatic cancer |
|
|
Gemcitabine resistance
|
upregulate hedgehog pathway
cells express stem cell markers CD44 |
|
|
Treating pancreatic cancer with gemcitabine resistance
|
gemcitabine
cyclopamine -inhibits hedgehog pathway |
